Sanofi Japan Looks Past Plavix Hit To New Launches
This article was originally published in PharmAsia News
Sanofi is facing a self-described “transitional period” in Japan and a couple of years of sales contraction as major products are opened up to generics. But the plan is to conduct more than 20 launches, including several biologics and line extensions, in the next four years, its new country president says.
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.